Buscador de publicaciones<< Volver

Husser O, Núñez J, Núñez E, Holzamer A, Camboni D, Luchner A, Sanchis J, Bodí V, Riegger GA, Schmid C, Hilker M, Hengstenberg C

Tumor marker carbohydrate antigen 125 predicts adverse outcome after transcatheter aortic valve implantation.

JACC Cardiovasc Interv. 2013 May;6(5):487-96, PMID: 23702013

This study sought to predict the value of tumor marker carbohydrate antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major adverse cardiac events [MACE]).

CARDIAC & CARDIOVASCULAR SYSTEMS

Descargar la publicación